100 related articles for article (PubMed ID: 8986135)
1. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction.
Köberle B; Payne J; Grimaldi KA; Hartley JA; Masters JR
Biochem Pharmacol; 1996 Dec; 52(11):1729-34. PubMed ID: 8986135
[TBL] [Abstract][Full Text] [Related]
2. Genetic basis of drug sensitivity in human testis tumour cells.
Wang X; Hafezparast M; Masters JR
Int J Cancer; 1996 Feb; 65(4):426-31. PubMed ID: 8621221
[TBL] [Abstract][Full Text] [Related]
3. DNA repair capacity and cisplatin sensitivity of human testis tumour cells.
Köberle B; Grimaldi KA; Sunters A; Hartley JA; Kelland LR; Masters JR
Int J Cancer; 1997 Mar; 70(5):551-5. PubMed ID: 9052754
[TBL] [Abstract][Full Text] [Related]
4. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
Rünger TM; Emmert S; Schadendorf D; Diem C; Epe B; Hellfritsch D
J Invest Dermatol; 2000 Jan; 114(1):34-9. PubMed ID: 10620112
[TBL] [Abstract][Full Text] [Related]
5. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Pera MF; Köberle B; Masters JR
Br J Cancer; 1995 May; 71(5):904-6. PubMed ID: 7734313
[TBL] [Abstract][Full Text] [Related]
6. Detection of DNA damage in transcriptionally active genes by RT-PCR and assessment of repair of cisplatin-induced damage in the glutathione S-transferase-pi gene in human glioblastoma cells.
Brandt TY; Ali-Osman F
Toxicol Appl Pharmacol; 1997 Mar; 143(1):22-9. PubMed ID: 9073588
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways.
Masters JR; Thomas R; Hall AG; Hogarth L; Matheson EC; Cattan AR; Lohrer H
Eur J Cancer; 1996 Jun; 32A(7):1248-53. PubMed ID: 8758261
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
10. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
11. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
12. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity.
Petersen LN; Mamenta EL; Stevnsner T; Chaney SG; Bohr VA
Carcinogenesis; 1996 Dec; 17(12):2597-602. PubMed ID: 9006094
[TBL] [Abstract][Full Text] [Related]
13. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.
Zeng-Rong N; Paterson J; Alpert L; Tsao MS; Viallet J; Alaoui-Jamali MA
Cancer Res; 1995 Nov; 55(21):4760-4. PubMed ID: 7585500
[TBL] [Abstract][Full Text] [Related]
14. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
To KK; Tong WS; Fu LW
Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
[TBL] [Abstract][Full Text] [Related]
15. Rapid polymerase chain reaction assay to detect variation in the extent of gene-specific damage between cisplatin- or VP-16-resistant and sensitive lung cancer cell lines.
Oshita F; Saijo N
Jpn J Cancer Res; 1994 Jul; 85(7):669-73. PubMed ID: 8071107
[TBL] [Abstract][Full Text] [Related]
16. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
[TBL] [Abstract][Full Text] [Related]
17. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
18. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
Taverna P; Hansson J; Scanlon KJ; Hill BT
Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
[TBL] [Abstract][Full Text] [Related]
19. Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity.
Awuah SG; Riddell IA; Lippard SJ
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):950-955. PubMed ID: 28096358
[TBL] [Abstract][Full Text] [Related]
20. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
Lanzi C; Perego P; Supino R; Romanelli S; Pensa T; Carenini N; Viano I; Colangelo D; Leone R; Apostoli P; Cassinelli G; Gambetta RA; Zunino F
Biochem Pharmacol; 1998 Apr; 55(8):1247-54. PubMed ID: 9719480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
